Nanomaterials for molecular signal amplification in electrochemical nucleic acid biosensing: recent advances and future prospects for point-of-care diagnostics

Bezinge, Léonard; Suea‐Ngam, Akkapol; deMello, Andrew J.; Shih, Chih‐Jen

doi:10.1039/c9me00135b

Cited by 61 publications

(33 citation statements)

References 167 publications

(202 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A possible variant of such an enhanced label consists in the formation of oligomeric complexes from several initial labels by their chemical conjugation or affine aggregation during the work of the sensor. (See recent reviews [62][63][64][65] with descriptions of such amplifying techniques.) (2) If it is necessary to expand the selectivity of the immunosensor, i.e., to increase the CR for structurally similar compounds recognized by the used antibodies, the opposite actions are required-an increase in the concentrations of antibodies and modified competing antigens and their use in a non-equimolar ratio.…”

Section: Potential Applicability Of the Presented Results To Biosensorsmentioning

confidence: 99%

Changing Cross-Reactivity for Different Immunoassays Using the Same Antibodies: Theoretical Description and Experimental Confirmation

et al. 2021

View full text Add to dashboard Cite

Many applications of immunoassays involve the possible presence of structurally similar compounds that bind with antibodies, but with different affinities. In this regard, an important characteristic of an immunoassay is its cross-reactivity: the possibility of detecting various compounds in comparison with a certain standard. Based on cross-reactivity, analytical systems are assessed as either high-selective (responding strictly to a specific compound) or low-selective (responding to a number of similar compounds). The present study demonstrates that cross-reactivity is not an intrinsic characteristic of antibodies but can vary for different formats of competitive immunoassays using the same antibodies. Assays with sensitive detection of markers and, accordingly, implementation at low concentrations of antibodies and modified (competing) antigens are characterized by lower cross-reactivities and are, thus, more specific than assays requiring high concentrations of markers and interacting reagents. This effect was confirmed by both mathematical modeling and experimental comparison of an enzyme immunoassay and a fluorescence polarization immunoassay of sulfonamides and fluoroquinolones. Thus, shifting to lower concentrations of reagents decreases cross-reactivities by up to five-fold. Moreover, the cross-reactivities are changed even in the same assay format by varying the ratio of immunoreactants’ concentrations and shifting from the kinetic or equilibrium mode of the antigen-antibody reaction. The described patterns demonstrate the possibility of modulating immunodetection selectivity without searching for new binding reactants.

show abstract

Section: Potential Applicability Of the Presented Results To Biosensorsmentioning

confidence: 99%

Changing Cross-Reactivity for Different Immunoassays Using the Same Antibodies: Theoretical Description and Experimental Confirmation

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Regarding nanomaterials, their multifunctional nature facilitates the improvement of several key features in electrochemical bioassays, including sample treatment, analyte capture, signal amplification and transduction. They have been widely used as electrode modifiers to improve the immobilization of bioreceptors and the charge transfer as well as advanced labels able to carry large amounts of electroactive reporters to amplify the electrochemical signals [ 75 ].…”

Section: Bioelectroanalytical Methods For the Determination Of Infmentioning

confidence: 99%

Revisiting Electrochemical Biosensing in the 21st Century Society for Inflammatory Cytokines Involved in Autoimmune, Neurodegenerative, Cardiac, Viral and Cancer Diseases

Campuzano

Yáñez‐Sedeño

Pingarrón

2020

Sensors

View full text Add to dashboard Cite

The multifaceted key roles of cytokines in immunity and inflammatory processes have led to a high clinical interest for the determination of these biomolecules to be used as a tool in the diagnosis, prognosis, monitoring and treatment of several diseases of great current relevance (autoimmune, neurodegenerative, cardiac, viral and cancer diseases, hypercholesterolemia and diabetes). Therefore, the rapid and accurate determination of cytokine biomarkers in body fluids, cells and tissues has attracted considerable attention. However, many currently available techniques used for this purpose, although sensitive and selective, require expensive equipment and advanced human skills and do not meet the demands of today’s clinic in terms of test time, simplicity and point-of-care applicability. In the course of ongoing pursuit of new analytical methodologies, electrochemical biosensing is steadily gaining ground as a strategy suitable to develop simple, low-cost methods, with the ability for multiplexed and multiomics determinations in a short time and requiring a small amount of sample. This review article puts forward electrochemical biosensing methods reported in the last five years for the determination of cytokines, summarizes recent developments and trends through a comprehensive discussion of selected strategies, and highlights the challenges to solve in this field. Considering the key role demonstrated in the last years by different materials (with nano or micrometric size and with or without magnetic properties), in the design of analytical performance-enhanced electrochemical biosensing strategies, special attention is paid to the methods exploiting these approaches.

show abstract

“… 41 , 42 Obtaining a high signal-to-noise ratio remains pivotal to detect even rare aberrant species in biological fluids. Therefore, analyte purification and signal amplification strategies 43 have been developed (e.g., based on the incorporation of magnetic beads that allow for magnetic extraction and concentration). 44 Indeed, integration of nanomaterials into point-of-care (POC) diagnostic devices has been shown to be highly beneficial for diagnosing and monitoring diseases at low costs and short time yet high sensitivity and specificity.…”

Section: What Makes a Good Diagnostic?mentioning

confidence: 99%

Optimizing nanoparticle design and surface modification toward clinical translation

Gessner

2021

MRS Bulletin

View full text Add to dashboard Cite

The field of nanomedicine is a rapidly evolving field driven by the need for safer and more efficient therapies as well as ultrasensitive and fast diagnostics. Although the advantages of nanoparticles for diagnostic and therapeutic applications are unambiguous, in vivo requirements, including low toxicity, long blood circulation time, proper clearance, sufficient stability, and reproducible synthesis have, in most cases, bedeviled their clinical translation. Nevertheless, researchers have the opportunity to have a decisive influence on the future of nanomedicine by developing new multifunctional molecules and adapting the material design to the requirements. Ultimately, the goal is to find the right level of functionality without adding unnecessary complexity to the system. This article aims to emphasize the potential and current challenges of nanoparticle-based medical agents and highlights how smart and functional material design considerations can help to overcome many of the current limitations and increase the clinical value of nanoparticles.

show abstract

Nanomaterials for molecular signal amplification in electrochemical nucleic acid biosensing: recent advances and future prospects for point-of-care diagnostics

Abstract: This account reviews the major amplification strategies utilizing nanomaterials in electrochemical biosensing for robust and sensitive molecular diagnostics.

Cited by 61 publications

References 167 publications

Changing Cross-Reactivity for Different Immunoassays Using the Same Antibodies: Theoretical Description and Experimental Confirmation

Changing Cross-Reactivity for Different Immunoassays Using the Same Antibodies: Theoretical Description and Experimental Confirmation

Revisiting Electrochemical Biosensing in the 21st Century Society for Inflammatory Cytokines Involved in Autoimmune, Neurodegenerative, Cardiac, Viral and Cancer Diseases

Optimizing nanoparticle design and surface modification toward clinical translation

Contact Info

Product

Resources

About